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Objective: Hyperoxia exposure leads to the development of lung injury and bronchial hyperreactivity (BHR) via
involvement of nitric oxide (NO) pathway. We aimed at characterizing whether the stimulation of the NO pathway
by sildenafil or vasoactive intestinal peptide (VIP) is able to prevent the hyperoxia-induced development of
BHR. The respective roles of the preserved lung volume and alveolar architecture, the anti-inflammatory and
anti-apoptotic potentials of these treatments in the diminished lung responsiveness were also characterized.
Materials and methods: Immature (28-day-old) rats were exposed for 72 hours to room air (Group C), hyperoxia
(>95%, Group HC), or hyperoxia with the concomitant administration of vasoactive intestinal peptide (VIP,
Group HV) or sildenafil (Group HS). Following exposure, the end-expiratory lung volume (EELV) was assessed
plethysmographically. Airway and respiratory tissue mechanics were measured under baseline conditions and
following incremental doses of methacholine to assess BHR. Inflammation was assessed by analyzing the
bronchoalveolar lavage fluid (BALF), while biochemical and histological analyses were used to characterize the
apoptotic and structural changes in the lungs.
Results: The BHR, the increased EELV, the aberrant alveolarization, and the infiltration of inflammatory cells into the
BALF that developed in Group HC were all suppressed significantly by VIP or sildenafil treatment. The number of
apoptotic cells increased significantly in Group HC, with no evidence of statistically significant effects on this
adverse change in Groups HS and HV.
Conclusions: These findings suggest that stimulating the NO pathway by sildenafil and VIP exert their beneficial
effect against hyperoxia-induced BHR via preserving normal EELV, inhibiting airway inflammation and preserving the
physiological lung structure, whereas the antiapoptotic potential of these treatments were not apparent in this process.Introduction
Prolonged exposure to excessive concentration of oxy-
gen is often applied in clinical practice to enhance oxy-
genation in the presence of compromised gas exchange.
While the adverse pulmonary consequences of oxygen-
toxicity have been well established, hyperoxia exposure* Correspondence: walid.habre@hcuge.ch
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unless otherwise stated.is required in clinical situations involving severely com-
promised oxygenation, such as in newborn infants with
premature birth [1-4] or in patients with acute lung in-
jury [5]. Since a prolonged excessive oxygen concentra-
tion poses the risk of long-term adverse alterations in
the lung architecture and pulmonary function [6], pre-
vention of hyperoxia-induced lung injury is still an issue
with major importance.
Hyperoxia provokes lung injury by inducing a primary
massive necrosis of capillary endothelial cells and hence
the loss of capillaries [7-9], which is followed by apoptosis/Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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alter the epithelial tight junctions with a subsequent
increase in alveolar-capillary barrier permeability leading
to pulmonary edema and induction of the inflammatory
cascade [10]. The chronic presence of all these patho-
physiological changes may lead to airway and vascular
remodeling in the lungs, with subsequent pulmonary
hypertension [2,11-14], fibrosis and the development of
irreversible changes in the lung structure [15-18]. All these
pathways contribute to the hyperoxia-induced develop-
ment of bronchial hyperreactivity (BHR) [13,14,16,17,19],
which plays a major role in the frequent development of
respiratory adverse events due to the enhanced lung
responsiveness to exogenous constrictor stimuli.
Previous studies demonstrated the deleterious effects
of hyperoxia on nitric oxide (NO) production in the
lungs via hyperoxia-induced epithelial and endothelial
cell injuries [20-22]. Therefore, the resulting imbalance
between the relaxation and constriction regulation of the
airway smooth muscle may be responsible for the ad-
verse lung functional and structural changes following
hyperoxia. Thus, enhancing NO production in the lungs
may counteract the elevated smooth muscle tone via a
direct effect [23] or prevent against the development
of chronic lung inflammation and subsequent airway
remodeling [24]. Similar to NO, vasoactive intestinal
peptide (VIP), which is also an inhibitory relaxant me-
diator of the non-adrenergic, non-cholinergic nervous
pathway, may also exhibit dual bronchodilatory and
anti-inflammatory potential [25-27]. Thus, we aimed
at investigating whether the restoration of the NO-
dependent processes with a phosphodiesterase type 5
(PDE5) inhibitor, such as sildenafil, or with VIP provides
an effective protection against the development of BHR
in the acute phase of hyperoxia. Furthermore, we also
intended to clarify whether the preserved lung structure,
or the anti-inflammatory and the anti-apoptotic poten-
tials of these treatments are responsible for the dimin-
ished lung responsiveness.
Materials and methods
Treatments and hyperoxia exposures
The experimental protocol was approved by the Experi-
mental Ethics Committee of the University of Geneva
and the Animal Welfare Committee of the Canton of
Geneva (1051/3691/II). Weanling male Sprague–Dawley
rats (80–125 g) were exposed to either hyperoxia (>95%
O2) or normoxia (room air, Group C, n = 8) for 72 hours.
The hyperoxia-exposed animals were randomized to 3
groups: no additional treatment (Group HC, n = 8), the
daily oral administration of sildenafil (20 mg/day; Pfizer,
Zürich, Switzerland Group HS, n = 7) or the daily i.p. in-
jection of VIP (150 μg/day; Sigma-Aldrich, Buchs,
Switzerland Group HV, n = 8), in both cases startingsimultaneously with the commencement of the exposure
to hyperoxia and lasting until the day prior to the exper-
iments. During the 72-hour oxygen or room air expos-
ure the rats were kept in a 98-liter sealed normobaric
Plexiglas chamber (Elega, Geneva, Switzerland). The
chamber was opened for a short time (<5 min) to allow
delivery of the daily treatment. The oxygen and CO2
levels were checked twice a day (Datex, Helsinki,
Finland). The CO2 level in the box was maintained
below 1% by using a CO2 absorber (Sodasorb, Asid Bonz
GmbH, Herrenberg, Germany). Food and water were
available ad libitum.
Experimental protocol
The rats were first anesthetized with an i.p. injection
of chloral hydrate (5%, 350 mg/kg; Sigma Aldrich,
Switzerland), then tracheostomized and the distal tra-
chea was cannulated with a polyethylene cannula (16 G,
13 mm long; AMSINO Medical, Shangai, China). The
animals were mechanically ventilated (model 683; Harvard
Apparatus, South Natick, MA, USA) with a tidal vol-
ume of 8 ml/kg, a respiratory rate of 110 breaths/min
and a positive end-expiratory pressure (PEEP) of 2.5
cmH2O. Anesthesia was maintained with the repeated
administration of 50 mg of chloral hydrate every hour.
After completion of the end-expiratory lung volume
(EELV) measurements, a femoral artery was cannulated
and attached to a pressure transducer (model 156 PCE
06-GW2; Honeywell, Zürich, Switzerland) to allow mon-
itoring of the systemic blood pressure. At the beginning
and at the end of the experiment, the arterial line was
also used for blood gas analysis (model 505; Acid Base
Laboratory, Copenhagen, Denmark). The femoral vein
was also catheterized for drug delivery. Since applica-
tion of the forced oscillation technique (FOT) to assess
the respiratory mechanics requires apnea, atracurium
(GlaxoSmithKline, Münchenbuchsee, Switzerland) was
administered i.v. before the measurements in order to
prevent the spontaneous breathing. This line was used for
the methacholine (MCh) provocation (Bichsel AG, Inter-
laken, Switzerland). At the end of the surgical prepar-
ation, a deep inspiration to a pressure of 30 cmH2O
was applied before the first FOT measurement so as
to standardize the volume history. The mechanical venti-
lation was then paused at end-expiration, and 4–6
6-s-long recordings were collected at 1-min intervals be-
tween each measurement under baseline conditions. To
assess the lung responsiveness MCh was infused i.v.
in incremental doses from 4 to 8 and 16 μg/kg/min.
The development of stable bronchoconstriction (airway
resistance values were within 5%) required 5 min. Three
forced oscillatory data recordings were collected and
ensemble-averaged under a steady-state conditions 6 min
after the onset of MCh provocation at each infusion level.
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the rat to recover from the bronchoconstriction and
3 further Zrs recordings were made and ensemble-
averaged.
At the end of the experiments, the right lung was
clamped near the bifurcation and bronchoalveolar lavage
fluid (BALF) was collected from the left lung 15 min
after the last Zrs measurements in order to assess lung
inflammation. For histological analyses, the right lung was
then instilled via the trachea with 4% formaldehyde at a
hydrostatic pressure of 20 cmH2O while the left lung was
clamped. A piece measuring ~0.5 cm3 was excised and
embedded in Optimal Cutting Temperature compound,
frozen in liquid nitrogen vapor-cooled 2-methylbutane
(Fluka Chemie GmbH, Buchs, Switzerland) and kept
at −80°C until cryosection and TUNEL analysis for apop-
tosis quantification.
Intratracheal pressure, systemic blood pressure, ECG
and rectal temperature were monitored throughout the
experiments (Biopac, Santa Barbara, CA, USA). Body
temperature was maintained at 37 ± 0.5°C through use ofa
homeothermic blanket system (Homeothermic monitor;
Harvard Apparatus, Edenbridge, UK).
The body weight and the basic blood gas parameters
of the rats included in the experimental groups at
the beginning of the experiments are demonstrated on
Table 1. The retarded BW in the Group HS is most
likely a consequence of the regular gavage. The higher
HCO3 in the animals of Group HC can be attributed to
the compensation of gas exchange abnormalities leading
to CO2 accumulation and chronic respiratory acidosis
during the hyperoxia exposure. Both treatments applied
in the animals in Groups HS and HV were able to main-
tain normal gas exchange.EELV measurements
EELV was measured at a PEEP of 2.5 cmH2O by using a
whole-body plethysmograph (620 ml), as detailed previ-
ously [28]. Briefly, the rat was placed in a supine position
in a sealed Plexiglas chamber. The tracheal cannula was
connected to the respirator and also to a pressurized (2.5
cmH2O) loudspeaker chamber. Before the measurement,Table 1 Anthropometric and blood gas data
Group C Group HC Group HS Group HV
BW (g) 102.9 ± 14.5 96.5 ± 6.6 87 ± 5.9 * 98.3 ± 8.9
pH 7.43 ± 0.07 7.39 ± 0.09 7.44 ± 0.1 7.41 ± 0.11
PCO2 (Kpa) 5.09 ± 0.8 5.97 ± 1.2
* 5.12 ± 1.7 5.06 ± 1.58
HCO3 (meq/l) 24.2 ± 1.8 30.5 ± 4.2
* 28.3 ± 6.5 23.1 ± 2.29
Mean ± SD of the body weight (BW), pH, partial pressure of CO2 and the
bicarbonate level (HCO3) in the arterial blood sample obtained at the
beginning of the experiment (day 4). *: p < 0.05 vs. Group C.the mechanical ventilation was paused, the plethysmograph
was opened to the atmosphere and the trachea was opened
to the loudspeaker chamber to equilibrate the lungs to a
pressure of 2.5 cmH2O. The airway opening and the ple-
thysmograph box were then closed until the first few
breathing efforts generated by the animal against the closed
trachea. Six-to-eight breathing maneuvers were recorded
for 10 s by measuring the tracheal (Ptr) and box (Pbox)
pressure changes. The recordings of Pbox were then cor-
rected for the thermal properties of the plethysmograph.
Via Boyle’s law, EELV was calculated from the rela-
tionship between the corresponding changes in Ptr
and Pbox [28].
Reliable EELV measurements were obtained in a sub-
group of animals, in view of the fact that the small
box pressure signals were recorded initially with the
use of a plethysmograph originally designed for adult
rats. The box volume was optimized for the size of
the weanling rats only after this technical problem had
been recognized.
Airway and tissue mechanics and bronchial challenge
The input impedance of the respiratory system (Zrs)
was estimated by FOT, as described in detail previously
[29]. Briefly, the tracheal cannula was connected to a
loudspeaker-in-box system generating a composite signal
containing 23 components at low frequencies (0.5-
20.75 Hz). The forcing signal was driven through a 100-
cm-long and 2-mm-ID polyethylene wave-tube into the
trachea during 6-s apneic periods. Two identical pressure
transducers (Model 33NA002D; ICSensors, Malpitas, CA,
USA) were used to measure the lateral pressures at the
loudspeaker and at the tracheal end of the wave-tube. Zrs
was calculated by applying the transmission line theory
[30]. A model including frequency-independent resistance
(Raw), inertance (Iaw) and a constant-phase tissue com-
partment with tissue parameters for damping (G) and
elastance (H) was fitted to the ensemble-averaged Zrs
spectra [31].
Data were corrected for body weight (BW). Zrs data
were measured under baseline conditions and following
i.v. methacholine (MCh) provocation (4, 8, 16 μg/kg/
min) to assess the lung responsiveness. The equivalent
dose causing a 50% increase in Raw (ED50) was calcu-
lated by linear interpolation.
Bronchoalveolar lavage
After completion of the last FOT measurements, BALF
was collected in order to analyze the inflammatory re-
sponse to hyperoxia in the lungs. The lungs were instilled
with 3 ml of PBS (37°C) via the tracheal cannula at a pres-
sure of 20 cmH2O. From the withdrawn BALF, the total
cell number was counted in a Neubauer hemocytometer
by using the trypan blue exclusion method. BALF was
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supernatant was collected to assess the protein content
(PIERCE BCA assay kit; Rockford, IL, USA). The cell
pellet was resuspended at 106 cells/ml in PBS con-
taining 1% BSA, and alveolar cell repartition was
determined on cytospin after May-Grünwald Giemsa
staining.Biochemical and histological analyses
The left lung was clamped, removed and preserved in
Optimal Cutting Temperature compound at −80°C. Ter-
minal deoxynucleotidyl transferase (TdT)-mediated deox-
yuridinetriphosphate (dUTP) nick end-labeling (TUNEL)
was performed on lung cryosections according to the
protocol for the In Situ Cell Death Detection Fluorescein
Kit (Roche, Mannheim, Germany). Briefly, 6-μm lung
slices were fixed with 4% formaldehyde for 10 min at
room temperature and next permeabilized for 2 min with
0.1% Triton X-100 in 0.1% sodium citrate at 4°C. The
slices were then incubated with the labeling mix contain-
ing TdT and fluorescein-labeled dUTP for 1 hour at 37°C.
Fluorescent staining of total nuclei was performed
with 250 ng/ml 4′,6-diamidino-2-phenylindole (Sigma)
for 5 min at room temperature. The slides were mounted
with FluorSave Reagent (Calbiochem, Nottingham, UK).
Images for analysis were acquired by confocal microscopy
(LSM 510 Meta; Carl Zeiss MicroImaging GmbH, Jena,
Germany) and cells were counted by using MetaFluor
Fluorescence Ratio Imaging Software (version 7.7.6;
Molecular Devices, Sunnyvale, USA). The percentage ratio
of the number of apoptotic nuclei from the total number
of nuclei was calculated.
The right lung was fixed with 4% formaldehyde under
a pressure of 20 cmH2O and embedded in paraffin. The
6-μm sections were stained with hematoxylin/eosin.
Full-section images were captured with a MIRAX MIDI
system (Carl Zeiss MicroImaging GmbH). Digitalized
images were analyzed by using Panoramic Viewer soft-
ware (3DHISTECH, Budapest, Hungary). Edema mani-
festation was quantified by relating the sum of edema
surface area around the bronchi and vasculature to the
total surface area of the lung tissue. Lung alveolar geo-
metric structure and density by mean linear intercept
(MLI) measurement was assessed by using the Image J
software (version 1.46r, NIH, Bethesda, USA).Statistical analysis
Data are presented as means ± SEM. The Shapiro-Wilk
test was used to test data for normality. The mechanical
parameters were normally distributed. Accordingly, two-
way repeated measures analysis of variances (ANOVA),
with variables of MCh dose (baseline, 4, 8, 16 μg/kg/min)
and groups (C, HC, HS and HV), was used to evaluate theeffects of hyperoxia on the lung responsiveness to the
bronchoconstrictor provocation.
To analyze the effects of hyperoxia on the inflamma-
tory response (total cell number, percentage of PMN
cells and protein), or on the functional and structural
changes (ED50, EELV, MLI and edema) and on the apop-
tosis, one-way ANOVA with the post hoc Holm-Šidák
test was used in the event of normal distribution. When
the distribution was not normal, ANOVA on ranks was
applied for the statistical analysis. p < 0.05 was consid-
ered statistically significant.
Results
Hyperoxia-induced lung hyperresponsiveness and
elevated lung volume
Figure 1 presents the results of the respiratory mechan-
ical measurements made in the protocol groups under
baseline condition and following provocations with in-
cremental i.v. doses of MCh. There was no evidence of a
statistically significant difference in the baseline values
of Raw · BW following hyperoxia exposure, whereas
G · BW was significantly elevated in Group HC (p < 0.01
vs. Group C), and H · BW was also higher in Groups
HC (p < 0.05) and HV (P < 0.01). The development of
airway hyperresponsiveness was apparent from the sig-
nificantly greater responses to MCh in the rats in Group
HC (p < 0.05 and p < 0.001, at the second and third
doses of MCh vs. Group C, respectively), whereas a
significant reduction in the lung responsiveness to MCh
was obvious in the hyperoxic rats treated with sildenafil
(Group HS, P < 0.001 at the third dose of MCh vs.
Group C) or VIP (Group HV, p < 0.001 at third dose
of MCh vs. Group C). The enhanced lung responsive-
ness in Group HC was also manifested in the signifi-
cantly greater increases in G · BW in response to MCh
(p < 0.005), whereas there was no evidence of an en-
hanced response in this parameter following either
sildenafil or VIP treatment. No statistically significant
treatment-dependent differences were observed in the
slight MCh-induced elevations in H · BW. All mechanical
parameters exhibited a complete recovery by 15 min after
the last MCh dose, with no statistically significant differ-
ence from their initial values.
The difference due to hyperoxia in the airway respon-
siveness to MCh is also reflected in the statistically sig-
nificantly decreased ED50 value (Figure 2A) in Group
HC as compared with Group C (p < 0.01). Both sildenafil
and VIP treatments significantly elevated this hyperoxia-
induced lowering in ED50 (p < 0.01 and p < 0.001, re-
spectively). EELV measurements were successfully made
in subgroups of 5 rats in each of Groups C and HC,
and of 4 animals in each of Groups HS and HV. Expos-
ure to hyperoxia significantly increased EELV in the
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Figure 1 Airway and respiratory tissue mechanical parameters
normalized to body weight (airway resistance: Raw · BW, tissue
damping: G BW, tissue elastance: H BW) under baseline
conditions, during methacholine challenges (MCh 4-8-16) and
after the bronchoprovocation tests (after MCh) in rats exposed
to room air (Group C) subjected to hyperoxia without any
additional treatment (Group HC) and hyperoxic rats treated
either with sildenafil (Group HS) or VIP (Group HV). *: p < 0.05
vs. Group C, #: p < 0.05 vs. Group HC.
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VIP treatments.
Effects of treatments on hyperoxia-induced lung
inflammation
The alterations in the cellular profile and the protein
content of the BALF are outlined in Figure 3. Hyperoxia
led to an increased number of inflammatory cells inthe BALF collected from the animals in Group HC
(Figure 3A, p < 0.001 vs. Group C and p < 0.01 vs.
Groups HS and HV). The repartition of the cell types
differed in Group HC from the other groups of rats;
the percentage of polymorphonuclear cells was signifi-
cantly increased (Figure 3B, p < 0.001 vs. Groups C, HS
and HV). The protein content of the supernatant was
significantly elevated in Group HC relative to Group C
(Figure 3C, p < 0.001), while there was no evidence of a
significant change in the sildenafil or VIP-treated ani-
mals as compared with Groups HC (Figure 3C).
Effects of treatments on the hyperoxia-induced lung
structural changes
The lung histological findings are depicted in Figure 4.
The lung sections of untreated animals subjected to
hyperoxia (Group HC, Figure 4A) revealed an aberrant
alveolarization with decreased alveolar septation and
consequently enlarged alveolar spaces in comparison
with normoxia-exposed lungs (Group C, Figure 4A).
These changes are expressed by the significantly in-
creased MLI value (Figure 4B, p < 0.001 vs. Group C).
When sildenafil (Group HS, Figure 4A) or VIP (Group
HV, Figure 4A) treatment was applied concomitantly
with hyperoxia, normal alveolarization was preserved, as
indicated by the MLI values, which exhibited no statisti-
cally significant difference from those for the normoxia
group (Figure 4B). The 72 hours of hyperoxia led to a
vascular leakage, as revealed by the edema around the
pulmonary vessels (Figure 4C). The ratio of the edema
surface area to the total surface area of the lung sections
was significantly greater in the non-treated animals
exposed to hyperoxia than in the controls (p < 0.001) or
in the hyperoxia-treated rats (p < 0.001 and p < 0.01 vs.
Group HS and HV, respectively).
Effects of treatments on the hyperoxia-induced apoptosis
For each lung cryosection, the total number of nuclei and
the number that were TUNEL-positive were counted in
10 independent randomized microscopic fields, represent-
ing at least 500 nuclei (506 to 1190); these results are
presented in Figure 5. Exposure to hyperoxia induced a
statistically significant increase in the percentage of
positive nuclei in Group HC relative to that in Group C
(p < 0.01). No evidence of statistically significant differ-
ences was observed in the sildenafil or VIP-treated rats
as concern the apoptosis in the lung cells when it was
compared to the untreated hyperoxic or normoxic
animals.
Discussion
The present study explored the lung function deterior-
ation and the development of an enhanced airway
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Figure 2 Equivalent doses of methacholine required to cause a 50% elevation in airway resistance (ED50, panel A) and the end-expiratory
lung volumes (EELV, panel B) measured in rats exposed to room air (Group C) subjected to hyperoxia without any additional treatment
(Group HC) and hyperoxic rats treated either with sildenafil (Group HS) or VIP (Group HV). *: p < 0.05 vs. Group C, #: p < 0.05 vs. Group HC.
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of hyperoxia on the baseline airway function, whereas oxy-
gen exposure induced deleterious changes in the baseline
values of the parameters reflecting dissipative and elastic
properties of the respiratory tissues, and marked eleva-
tions in the end-expiratory static lung volume. The results
also demonstrated that the PDE5-inhibitor sildenafil and
the NO-liberator VIP abolished the hyperoxia-induced de-
velopment of airway hyperresponsiveness. These beneficial
properties were associated with the abilities of both treat-
ments to maintain normal EELV, preserving the normal
alveolarization, exerting a beneficial effect on the inflam-
matory response and preventing the edema formation in
the developing lung during hyperoxia exposure. However,
none of the treatments proved beneficial in the inhibition
of the hyperoxia-induced apoptosis.
The immature rat model was chosen in the present
study, since hyperoxia exposure is often required in
clinical situations involving severely compromised oxygen-
ation, such as in infants [2,32]. To address the prevention
of BHR appropriately, respiratory mechanical measure-
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Figure 3 Total cells (panel A), the repartition to polymorphonuclear c
obtained from rats exposed to room air (Group C) subjected to hype
rats treated either with sildenafil (Group HS) or VIP (Group HV). *: p <intended to apply intravenous delivery of the provocation
agonist, as this route of administration gives more repre-
sentative picture about the overall lung response [33]. The
need for securing venous and arterial lines for reliable
respiratory mechanical measurements necessitated the
use of weanling rats rather than much younger rat pups.
Nevertheless, the findings obtained in our model can be
also generalized to adult patients with acute lung injury,
where a prolonged excessive oxygen exposure is also part
of the therapy [5].
Respiratory function and lung responsiveness
In accordance with earlier results when immature rats
were exposed to oxygen for a short time [16], the basal
Raw was not affected by hyperoxia exposure (Figure 1)
and is also in line with the notion that Raw is deter-
mined primarily by the geometry of the central conduct-
ing airways, which remained unaffected [19,34,35]. An
airway obstruction was detected in earlier studies when
exposure to oxygen was applied for a prolonged period
(e.g. 4 weeks), which was sufficient for airway remodel-
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ells (panel B) and the protein content (panel C) of the BALF
roxia without any additional treatment (Group HC) and hyperoxic
0.05 vs. Group C, #: p < 0.05 vs. Group HC.
Figure 4 Representative images of hematoxylin/eosin-stained lung sections (panel A) collected from control rats exposed to room air
(C), rats subjected to hyperoxia without any additional treatment (HC), and hyperoxic rats treated with either sildenafil (HS) or VIP
(HV). Mean linear intercept values (panel B) and percentage of edema surface (panel C) were determined from the lung sections of the rats in
the protocol groups. *: p < 0.05 vs. Group C, #: p < 0.05 vs. Group HC.
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study resulted in increases in the basal values of both
viscoelastic tissue parameters (Figure 1; G · BW and H ·
BW), which accords with the results of previous studies,
where a decreased compliance was found after oxygen
toxicity [19,36-38]. Since the hyperoxia-induced in-
creases in G · BW and H · BW were proportional, the
enhancement of ventilation heterogeneities was not
likely to have played a role in these findings [39]. It
seems more probable that perivascular and interstitial
edema formation are responsible for these proportionalelevations, this being substantiated by the histological
findings (Figure 4C) and the elevated protein level in
the BALF (Figure 3C). Nevertheless, other processes
may also have been involved in the increase in H · BW,
since an elevation in elastance was also observed in
the VIP-treated rats, despite the lack of manifest edema.
Such processes may be related to hyperventilation
throughout the exposure, striving to compensate the
hyperoxia and causing hypertrophy of the intercostal
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Figure 5 Percentages of TUNEL-positive nuclei counted in lung cryosections (panel A) collected from rats exposed to room air (Group
C) subjected to hyperoxia without any additional treatment (Group HC) and hyperoxic rats treated either with sildenafil (Group HS) or
VIP (Group HV). *: p < 0.05 vs. Group C, #: p < 0.05 vs. Group HC. Representative images for TUNEL in cryosections from the studied groups are
shown in panel B. Arrows indicate TUNEL-positive nuclei (green).
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hyperresponsiveness at 72 hours after the onset of hyper-
oxia, manifested in a decreased ED50 value (Figure 2A), in
accordance with the results of the few previous studies
where bronchoprovocation tests were performed [16,38,40].
It is noteworthy that this functional abnormality is already
present despite the lack of remodeling of the bronchial wall
at this acute stage of oxygen toxicity [34].
While the presence of BHR was consistently estab-
lished in earlier studies after hyperoxia exposures, the
efficient prevention of this major pulmonary symptom
has not been investigated. The main finding of the
present study is that both sildenafil and VIP compen-
sated and even overcompensated the enhanced lung
responsiveness. To address the role of the mechanisms
responsible for this finding in detail, alveolar structural
and lung configurational changes, inflammatory alter-
ation and biochemical profile were compared between
the protocol groups.
Role of lung morphological changes in the abolished BHR
In our hyperoxia model, the 72-hour oxygen exposure
was sufficiently long for an abnormal alveolar structure
to be observed in the developing lungs (Figure 4A).
Compensation of the previously demonstrated decreased
NO activity [20,22], either through stimulation of the
cyclic guanosine monophosphate-dependent effects by
using sildenafil to activate vascular endothelial growth
factor [41], or through enhancement of the NO produc-
tion by VIP treatment was able to preserve normal
alveolarization despite maintenance of the hyperoxic
environment (Figure 4). Counting MLI confirmed thatenlarged alveolar spaces were observed only in the non-
treated oxygen-exposed animals; in the other groups,
the MLI data were normal. These findings point to
the involvement of the preserved physiological alveolar
structure in the protection of the adverse lung functional
changes following prolonged oxygen exposure and suggest
its contribution to the abolishment of the hyperoxia-
induced BHR.
Role of preserved normal lung volume in the abolished BHR
While lung functional changes have been well estab-
lished following hyperoxia-induced lung injury, and this
damage has been reported to increase terminal air space
size [42], we are unaware of any previous papers ad-
dressing the changes in the static volumes in a develop-
ing lung. Thus, our finding is the first to reveal that
the changes in alveolar architecture were also reflected
in the hyperoxia-induced EELV elevation in Group HC
(Figure 2A). In this emphysematous condition, air is
trapped in the enlarged alveolar spaces at end-expiration
and the gas content of the chest is increased. Moreover,
the small airways are likely to display a tendency to
collapse during expiration due to their structural impair-
ment, and their function may be further compromised
by the decreased elastic support of the damaged lung
parenchyma, which would be less able to keep the small
airways open. Since the sildenafil and VIP prevented
the enlargement of terminal airspaces, the physiological
EELV in these animals is in line with the histological
findings. This further confirms the abilities of these
treatments to preserve physiological lung configuration
during hyperoxia exposures.
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Since the inflammatory cells appear in the first few
hours of hyperoxia exposure [43], early inhibition of the
inflammatory response might prevent the lung injury
and thus, this pathway is expected to contribute to the
development of BHR. As confirmed by our findings
(Figure 3A, B), VIP was shown to protect alveolar epi-
thelial cells against hyperoxia via decreasing neutrophil
influx into the lung [27,44]. Thus, treatments with
sildenafil or VIP protect against the deleterious conse-
quences of hyperoxia-induced lung inflammation by
inhibiting polymorphonuclear cell infiltration into the
alveolar compartment and reducing the consecutive
tissue destruction. This beneficial profile of NO may
be related to the down-regulation of the intracellu-
lar adhesion molecule and monocyte chemotactic
protein-1 [45]. These findings indicate that the potent
anti-inflammatory activities of sildenafil and VIP play a
key role in the prevention of functional abnormalities,
including the development of BHR, following acute
hyperoxia exposures.
Role of alveolo-capillary disruption in the abolished BHR
Elevated amounts of reactive oxygen species (ROS) are
known to cause alterations in DNA and proteins and
are the major contributors to alveolar cell death in
hyperoxia [9,46]. The alveolar cell death is an early
event in hyperoxia-induced lung injury [9,47]. In agree-
ment with the literature finding, the number of apop-
totic/necrotic cells in rat lung was elevated following
exposure to hyperoxia for 72 hours. However, there was
no evidence for sildenafil or VIP to prevent apoptosis
and necrosis (Figure 5), suggesting that the preserved
lung function and responsiveness in these animals are
not related to the abilities of the these treatments to
counteract the initial ROS injuries. Accordingly, the
anti-apoptotic potential of sildenafil and VIP does not
contribute to the abolished hyperoxia-induced BHR
despite the presence of a close link between the apop-
tosis and BHR [48,49].
Other potential contributing mechanisms in the abolished
BHR
A further potential explanation for the abolished BHR
following hyperoxia exposures may be related to the dir-
ect effects of the treatments on the lung responsiveness.
Since excessive NO production exerts a potent smooth
muscle relaxation [23], this may have counteracted the
MCh-induced constrictor stimuli, and subsequently di-
minished the airway responsiveness. This possible effect
is due to the direct functional antagonism of the con-
strictor stimuli and thus, its efficiency may be independ-
ent from the presence of lung injury. Since the half-life
of sildenafil is 3–6 hours [50] and it is even muchshorter for VIP [51], and both treatments were termi-
nated on the days before the experiment, this direct
mechanism was unlikely to play a detectable role.
Conclusions
The results of the present study demonstrate that enhan-
cing the activity of NO-mediated pathways by sildenafil
and VIP prevent the development of hyperoxia-induced
BHR by preserving normal alveolarization, preventing
lung volume enlargement, and inhibiting lung inflam-
mation and edema formation. The lack of prophylactic
activities of sildenafil and VIP against hyperoxia-induced
apoptosis despite the abolished BHR suggests that this
pathway did not contribute to the enhanced lung respon-
siveness. Our findings therefore point to the potential
benefit of sildenafil or VIP treatment in the critical acute
phase of hyperoxic lung damage by demonstrating their
abilities not only to prevent the irreversible functional
and structural changes in the lungs, but also to preserve
physiological lung responsiveness.
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